News

The Open Source Imaging Consortium (OSIC), a nonprofit collaborative group focused on combatting lung diseases, announced the winners of a competition that challenged scientists to design artificial intelligence (AI) programs that predict lung function decline in people with pulmonary fibrosis. Broadly, AI refers to computer systems that are able…

People with prediabetes or diabetes who live in smog-filled cities may be more prone to pulmonary fibrosis as a result of exposure to ozone, a study in mice indicates. The study, “Repetitive Ozone Exposures and Evaluation of Pulmonary Inflammation and Remodeling in Diabetic Mouse Strains,” was published…

Idiopathic pulmonary fibrosis (IPF) negatively affects a person’s health-related quality of life (HRQoL), especially their physical health, a review study suggests. Patients’ age and disease severity also were found to have an impact on HRQoL. The study, “Health-related quality of life of patients with idiopathic pulmonary fibrosis: a…

iBio has received a U.S. patent for its method of increasing the amount and quality of endostatin-derived peptides generated from the company’s plant-based FastPharming protein production system. These peptides, which have been shown to possess strong anti-fibrotic or anti-scarring properties, make up part of IBIO-100, an experimental…

The U.S. Food and Drug Administration (FDA) has granted treprostinil orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug designation is given to therapies with the potential to substantially improve treatment for rare diseases (conditions affecting fewer than 200,000 people in the U.S.). The designation…

The global COVID-19 pandemic has had a negative local impact on healthcare for most people in the U.K. with pulmonary fibrosis (PF), who have seen their medical appointments canceled, their pulmonary rehabilitation programs halted, and their health status decline as a result of lockdowns and other safety measures,…

The nonprofit Three Lakes Foundation and the healthcare incubator MATTER announced the four winners of the 2020 Innovation Challenge, an initiative that promotes advancements in the way pulmonary fibrosis (PF) is diagnosed, treated, and managed. Winners of the challenge will receive a monetary award…

GLPG1205, an investigational therapy by Galapagos, was found to be safe and well tolerated, with an ability to lower lung function decline in adults with idiopathic pulmonary fibrosis (IPF), according to results from a Phase 2 clinical trial. Top-line data from the study, called PINTA (…

A Phase 3 clinical trial evaluating Bellerophon Therapeutics’ investigational therapy INOpulse — inhaled nitric oxide — in patients with pulmonary fibrosis (PF) at risk of developing pulmonary hypertension (PH) has enrolled its first patient. Top-line data from the trial, called REBUILD (NCT03267108), are expected by 2022. “We…

To empower and equip members of the rare disease community to engage state leaders in matters of importance to patients and their families, the National Organization for Rare Disorders (NORD) has launched an initiative across the U.S. Its goal is to establish a Rare Disease Advisory Council (RDAC)…